American Express Co

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market a diverse portfolio of therapeutic products. Among its commercialized treatments are ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor designed to address paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company also offers SOLIRIS (eculizumab), a monoclonal antibody approved for PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Further offerings include Strensiq (asfotase alfa), an enzyme replacement therapy targeting hypophosphatasia, and Kanuma (sebelipase alfa), used in the management of lysosomal acid lipase deficiency. Alexion's robust pipeline includes several investigational compounds. ALXN1210 is undergoing Phase III clinical trials in both intravenous (for gMG and NMOSD) and subcutaneous (for PNH and aHUS) formulations. Other early-stage programs feature ALXN1810 (subcutaneous) in Phase I for renal diseases, and ALXN1720 (subcutaneous) also in Phase I, aimed at conditions linked to dysregulated terminal complement activity. Additionally, Alexion is advancing ALXN1840 (WTX101) through Phase III trials for Wilson disease, alongside ALXN1830 and ABY-039, both in Phase I studies for indications related to the neonatal Fc receptor. Its global customer base encompasses a range of healthcare entities, including distributors, pharmacies, hospitals, and hospital buying groups, across the United States and international markets. Alexion maintains numerous strategic alliances and partnerships, notably a collaboration and license agreement with Halozyme Therapeutics, Inc. It also collaborates with Caelum Biosciences, Inc. (with whom it also has a strategic agreement), Dicerna Pharmaceuticals, Inc., and Zealand Pharma A/S, holds an agreement with Stealth BioTherapeutics Corp., and partners with Affibody AB. Established in 1992, Alexion Pharmaceuticals operates from its headquarters in Boston, Massachusetts.